Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene Corporation (CELG)'s Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma  
8/1/2012 10:23:58 AM

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced it has initiated patient enrollment in a new Phase 1b clinical trial of its lead drug candidate rocilinostat (ACY-1215) in combination with Revlimid® (lenalidomide) and dexamethasone for the treatment of relapsed and relapsed/refractory multiple myeloma. Rocilinostat is an oral Class II histone deacetylase (HDAC) inhibitor selective for the intracellular enzyme HDAC6. Acetylon believes that selective HDAC6 inhibition may provide enhanced anti-cancer effectiveness through potentially improved tolerability compared to current non-selective inhibitors, which inhibit both Class I and Class II HDACs. Celgene is providing free access to its disease-altering therapy, Revlimid®, for patients participating the clinical trial.